Sun., October 15, 2023 | The Associated Press Share Share

太阳。，2023年10月15日|关联新闻分享

A sign for Eli Lilly & Co. stands outside their corporate headquarters in Indianapolis on April 26, 2017. A new study finds that the medicine in the diabetes drug Mounjaro helped people with obesity or who are overweight lose at least a quarter of their body weight. (AP Photo/Darron Cummings, File)

2017年4月26日，礼来公司的标志位于印第安纳波利斯的公司总部之外。一项新的研究发现，糖尿病药物Mounjaro中的药物帮助肥胖或超重的人减轻至少四分之一的体重。（AP照片/Darron Cummings，文件）

The medicine in the diabetes drug Mounjaro helped people with obesity or who are overweight lose at least a quarter of their body weight, or about 60 pounds on average, when combined with intensive diet and exercise, a new study shows.By comparison, a group of people who also dieted and exercised, but then received dummy shots, lost weight initially but then regained some, researchers reported Sunday in the journal Nature Medicine.

一项新的研究显示，糖尿病药物Mounjaro中的药物帮助肥胖或超重的人在与强化饮食和运动相结合时，平均减轻至少四分之一的体重，或平均约60磅。相比之下，研究人员星期日在“自然医学”杂志上报道，一群同时节食和锻炼但随后接受虚拟射击的人最初体重减轻，但后来又恢复了一些体重。

“This study says that if you lose weight before you start the drug, you can then add a lot more weight loss after,” said Dr. Thomas Wadden, a University of Pennsylvania obesity researcher and psychology professor who led the study. The results, which were also presented Sunday at a medical conference, confirm that the drug made by Eli Lilly & Co.

“这项研究表明，如果你在开始服药前减肥，那么你可以在之后增加更多的体重减轻，”宾夕法尼亚大学肥胖研究员和心理学教授Thomas Wadden博士说。研究结果也在星期日的医学会议上公布，证实了礼来公司生产的药物。

has the potential to be one of the most powerful medical treatments for obesity to date, outside experts said. “Any way you slice it, it's a quarter of your total body weight,' said Dr. Caroline Apovian, who treats obesity at Brigham and Women's Hospital and wasn't involved in the study. The injected drug, tirzepatide, was approved in the U.S.

外部专家说，有可能成为迄今为止最有效的肥胖药物之一。Caroline Apovian博士在布莱根妇女医院治疗肥胖症，并没有参与这项研究，他说：“无论如何，你切片，这是你总体重的四分之一。”注射的药物tirzepatide在美国获得批准。

in May 2022 to treat diabetes. Sold as Mounjaro, it has been used “off-label” to treat obesity, joining a frenzy of demand for diabetes and weight-loss medications including Ozempic and Wegovy, made by Novo Nordisk.All the drugs, which carry retail price tags of $900 a month or more, have been in shortage for months.Tirzepatide targets two hormones that kick in after people eat to regulate appetite and the feeling of fullness communicated between the gut and the brain.

在2022年5月治疗糖尿病。作为Mounjaro出售，它已被用于“非标签”治疗肥胖症，加入了由Novo Nordisk制造的对糖尿病和减肥药物（包括Ozempic和Wegovy）的需求热潮。所有带有零售价格标签的药物每月900美元或更长时间，几个月来一直短缺。Tirzepatide的目标是两种激素，在人们进食后启动，以调节食欲和肠道与大脑之间传达的饱腹感。

Semaglutide, the drug used in Ozempic and Wegovy, targets one of those hormones.The new study, which was funded by Eli Lilly, enrolled about 800 people who had obesity or were overweight with a w.

Semaglutide是Ozempic和Wegovy中使用的药物，针对其中一种激素。这项由礼来公司资助的新研究招募了大约800名肥胖或超重的人。